Immunohistochemical Determination of HIF, TSP-1, ADAMTS1, and ADAMTS8 Expressions in the Brains of Alzheimer's Disease Patients: A Preliminary Autopsy Study

被引:2
|
作者
Inanir, Nursel Turkmen [1 ]
Eren, Filiz [2 ]
Fedakar, Recep [1 ]
Eren, Bulent [2 ]
Demircan, Kadir [3 ]
Gurses, Murat Serdar [1 ]
Ural, Mustafa [1 ]
Akyol, Sumeyya [3 ]
Aynekin, Busra [3 ]
机构
[1] Uludag Univ, Sch Med, Dept Forens Med, Bursa, Turkey
[2] Council Forens Med Turkey, Bursa Morgue Dept, Bursa, Turkey
[3] Turgut Ozal Univ, Sch Med, Dept Med Biol, Ankara, Turkey
关键词
Alzheimer's disease; ADAMTS1; HIF-1; ADAMTS8; TSP-1;
D O I
10.5152/etd.2016.0061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Alzheimer's disease (AD) is a progressive neurodegenerative disease that mostly affects the elderly population. Recent studies performed in AD highlight the pathophysiological relevance of disintegrin and metalloproteinase with thrombospondin type 1-like motifs (ADAMTS) genes and their products, namely hypoxia inducible factor-1 (HIF-1) and thrombospondin-1 (TSP-1). Thus, the aim of this study was to describe and identify the distribution, characteristics, and any changes in the expression and immunoreactivity for HIF-1, TSP-1, and ADAMTS1 and 8 in AD brains. Materials and Methods: Nine patients who were autopsied in the Council of Forensic Medicine, Bursa Morgue Department in 2013, were selected. All patients were sent for autopsy to the Morgue Department within 8 h after death. At the autopsy, tissue samples of the organs were obtained for histopathological examination for determining the cause of death. Among these, two patients were clinically diagnosed with AD. Results: Immunohistochemical staining was performed, and the staining intensity/extensity was evaluated using a semi-quantitative scoring system. Median distribution (extensity) scores of the immunohistochemical staining were estimated as 2 for HIF-1, 0.67 for TSP-1, 3.11 for ADAMTS1, and 2.78 for ADAMTS8. Intensity scores were estimated as 1.22 for HIF-1, 0.56 for TSP-1, 3 for ADAMTS1, and 2.11 for ADAMTS8. Conclusion: Our study suggests that ADAMTS1 and ADAMTS8 expressions are not specific for AD. To understand and provide definitive data on all aspects of metalloproteinases, extracellular matrix proteins, and transcriptional factor effects to AD, further studies are needed, where other metalloproteinases and related molecules/enzymes should be studied.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 8 条
  • [1] ADAMTS4, 5, 9, and 15 Expressions in the Autopsied Brain of Patients with Alzheimer's Disease: A Preliminary Immunohistochemistry Study
    Pehlivan, Sultan
    Fedakar, Recep
    Eren, Bulent
    Akyol, Sumeyya
    Eren, Filiz
    Inanir, Nursel Turkmen
    Gurses, Murat Serdar
    Ural, Mustafa Numan
    Tagil, Suleyman Murat
    Demircan, Kadir
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 26 (01): : 7 - 14
  • [2] Immunohistochemical study of the hnRNP A2 and B1 in the hippocampal formations of brains with Alzheimer's disease
    Mizukami, K
    Ishikawa, M
    Iwakiri, M
    Ikonomovic, MD
    Dekosky, ST
    Kamma, H
    Asada, T
    NEUROSCIENCE LETTERS, 2005, 386 (02) : 111 - 115
  • [3] Immunohistochemical study of hnRNP B1 in the postmortem temporal cortices of patients with Alzheimer's disease
    Ishikawa, M
    Mizukami, K
    Iwakiri, M
    Kamma, H
    Ikonomovic, MD
    Dekosky, ST
    Asada, T
    NEUROSCIENCE RESEARCH, 2004, 50 (04) : 481 - 484
  • [4] Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies - an immunohistochemical study
    Shiozaki, K
    Iseki, E
    Hino, H
    Kosaka, K
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2001, 193 (01) : 23 - 28
  • [5] Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Aβ expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study
    Vinothkumar, G.
    Krishnakumar, S.
    Sureshkumar
    Shivashekar, G.
    Sreedhar, S.
    Preethikrishnan
    Dinesh, S.
    Sundaram, A.
    Balakrishnan, D.
    Riya
    Venkataraman, P.
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 104 : 211 - 222
  • [6] Common 1H-MRS Characteristics in Patients With Alzheimer's Disease and Vascular Dementia Diagnosed With Kidney Essence Deficiency Syndrome: A Preliminary Study
    Guo, Zhongwei
    Liu, Xiaozheng
    Cao, Yulin
    Hou, Hongtao
    Chen, Xingli
    Chen, Yongcan
    Huang, Feihua
    Chen, Wei
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2017, 23 (03) : 12 - 18
  • [7] Results of a Phase 1 Study of ABBV-8E12 in Patients with Progressive Supranuclear Palsy and Phase 2 Study Design in Alzheimer's Disease and PSP
    Florian, Hana
    West, Tim
    Braunstein, Joel
    Fogelman, Ilana
    Bordelon, Yvette
    Litvan, Irene
    Roberson, Erik
    Hu, Helen
    Verghese, Philip
    Bateman, Randall
    Mendonca, Nuno
    Wang, Deli
    Ryman, Davis
    Gault, Laura
    Budur, Kumar
    Rendenbach-Mueller, Beatrice
    Kerwin, Diana
    Boxer, Adam
    Holtzman, David
    NEUROLOGY, 2017, 89 (08) : E99 - E100
  • [8] A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease
    Nathan, Pradeep. J. J.
    Millais, S. Babli
    Godwood, Alex
    Dewit, Odile
    Cross, David. M. M.
    Liptrot, Janet
    Ruparelia, Bharat
    Jones, Stephen Paul
    Bakker, Geor
    Maruff, Paul. T. T.
    Light, Gregory. A. A.
    Brown, Alastair J. H.
    Weir, Malcolm Peter
    Congreve, Miles
    Tasker, Tim
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2022, 8 (01)